NASDAQ:PRVBProvention Bio Stock Price, Forecast & News

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRVB shares have increased by 48.8% and is now trading at $13.41. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Provention Bio.

Provention Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Provention Bio.

Provention Bio Inc (NASDAQ:PRVB) released its earnings results on Thursday, May, 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. View Provention Bio's earnings history.

4 analysts have issued 12 month price objectives for Provention Bio's stock. Their forecasts range from $20.00 to $35.00. On average, they expect Provention Bio's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 105.1% from the stock's current price. View analysts' price targets for Provention Bio.

News headlines about PRVB stock have been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Provention Bio earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the next few days. View the latest news aboutProvention Bio.

Provention Bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,760,000 shares, an increase of 13.1% from the April 30th total of 2,440,000 shares. Based on an average daily trading volume, of 578,400 shares, the days-to-cover ratio is currently 4.8 days. Currently, 8.1% of the shares of the stock are short sold. View Provention Bio's Current Options Chain.

Some companies that are related to Provention Bio include Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), TG Therapeutics (TGTX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), Epizyme (EPZM), Pacira Biosciences (PCRX), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR) and Aurinia Pharmaceuticals (AUPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Myovant Sciences (MYOV), VBI Vaccines (VBIV), NVIDIA (NVDA), Opko Health (OPK), Vaxart (VXRT) and Clovis Oncology (CLVS).

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Provention Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.31%), BlackRock Inc. (1.43%), Invesco Ltd. (1.06%), Geode Capital Management LLC (0.61%), Segantii Capital Management Ltd (0.60%) and EAM Global Investors LLC (0.30%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, Peter A Appel and Wayne Pisano. View institutional ownership trends for Provention Bio.

PRVB stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Baker Avenue Asset Management LP, Lido Advisors LLC, Wells Fargo & Company MN, Bailard Inc., Virtus ETF Advisers LLC, State Street Corp, and Sigma Planning Corp. View insider buying and selling activity for Provention Bio.

PRVB stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., EAM Global Investors LLC, EAM Investors LLC, Perceptive Advisors LLC, Sontag Advisory LLC, Rice Hall James & Associates LLC, Jane Street Group LLC, and Geode Capital Management LLC. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, Peter A Appel, and Wayne Pisano. View insider buying and selling activity for Provention Bio.

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRVB stock can currently be purchased for approximately $13.41.

Provention Bio has a market capitalization of $640.19 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 13 workers across the globe.

The official website for Provention Bio is www.proventionbio.com.

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]